Fusing Artificial Intelligence and Machine Learning for Anti-Cancer Drug Discovery

Adamopoulos,Papavassiliou,Papavassiliou

DOI: https://doi.org/10.3390/cancers16203522

2024-10-18

Cancers

Abstract:The integration of artificial intelligence (AI) and machine learning (ML) in modern oncology is rapidly transforming cancer drug discovery and development [...]

oncology

What problem does this paper attempt to address?

Artificial intelligence for small molecule anticancer drug discovery

Lihui Duo Yu Liu Jianfeng Ren Bencan Tang Jonathan D. Hirst a Faculty of Science and Engineering,University of Nottingham Ningbo China,Ningbo,Chinab School of Chemistry,University of Nottingham University Park,Nottingham,UK

DOI: https://doi.org/10.1080/17460441.2024.2367014

2024-06-19

Expert Opinion on Drug Discovery

Abstract:Introduction The transition from conventional cytotoxic chemotherapy to targeted cancer therapy with small-molecule anticancer drugs has enhanced treatment outcomes. This approach, which now dominates cancer treatment, has its advantages. Despite the regulatory approval of several targeted molecules for clinical use, challenges such as low response rates and drug resistance still persist. Conventional drug discovery methods are costly and time-consuming, necessitating more efficient approaches. The rise of artificial intelligence (AI) and access to large-scale datasets have revolutionized the field of small-molecule cancer drug discovery. Machine learning (ML), particularly deep learning (DL) techniques, enables the rapid identification and development of novel anticancer agents by analyzing vast amounts of genomic, proteomic, and imaging data to uncover hidden patterns and relationships.

pharmacology & pharmacy
Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery

Nagasundaram Nagarajan,Edward K. Y. Yapp,Nguyen Quoc Khanh Le,Balu Kamaraj,Abeer Mohammed Al-Subaie,Hui-Yuan Yeh

DOI: https://doi.org/10.1155/2019/8427042

2019-11-11

BioMed Research International

Abstract:Artificial intelligence (AI) proves to have enormous potential in many areas of healthcare including research and chemical discoveries. Using large amounts of aggregated data, the AI can discover and learn further transforming these data into “usable” knowledge. Being well aware of this, the world’s leading pharmaceutical companies have already begun to use artificial intelligence to improve their research regarding new drugs. The goal is to exploit modern computational biology and machine learning systems to predict the molecular behaviour and the likelihood of getting a useful drug, thus saving time and money on unnecessary tests. Clinical studies, electronic medical records, high-resolution medical images, and genomic profiles can be used as resources to aid drug development. Pharmaceutical and medical researchers have extensive data sets that can be analyzed by strong AI systems. This review focused on how computational biology and artificial intelligence technologies can be implemented by integrating the knowledge of cancer drugs, drug resistance, next-generation sequencing, genetic variants, and structural biology in the cancer precision drug discovery.

biotechnology & applied microbiology,medicine, research & experimental
Artificial Intelligence and Anticancer Drug Development—Keep a Cool Head

Caroline Bailleux,Jocelyn Gal,Emmanuel Chamorey,Baharia Mograbi,Gérard Milano

DOI: https://doi.org/10.3390/pharmaceutics16020211

IF: 6.525

2024-02-01

Pharmaceutics

Abstract:Artificial intelligence (AI) is progressively spreading through the world of health, particularly in the field of oncology. AI offers new, exciting perspectives in drug development as toxicity and efficacy can be predicted from computer-designed active molecular structures. AI-based in silico clinical trials are still at their inception in oncology but their wider use is eagerly awaited as they should markedly reduce durations and costs. Health authorities cannot neglect this new paradigm in drug development and should take the requisite measures to include AI as a new pillar in conducting clinical research in oncology.

pharmacology & pharmacy
Artificial Intelligence-Driven Computational Approaches in the Development of Anticancer Drugs

Pankaj Garg,Gargi Singhal,Prakash Kulkarni,David Horne,Ravi Salgia,Sharad S Singhal

DOI: https://doi.org/10.3390/cancers16223884

2024-11-20

Abstract:The integration of AI has revolutionized cancer drug development, transforming the landscape of drug discovery through sophisticated computational techniques. AI-powered models and algorithms have enhanced computer-aided drug design (CADD), offering unprecedented precision in identifying potential anticancer compounds. Traditionally, cancer drug design has been a complex, resource-intensive process, but AI introduces new opportunities to accelerate discovery, reduce costs, and optimize efficiency. This manuscript delves into the transformative applications of AI-driven methodologies in predicting and developing anticancer drugs, critically evaluating their potential to reshape the future of cancer therapeutics while addressing their challenges and limitations.
Applied machine learning in cancer research: A systematic review for patient diagnosis, classification and prognosis

Konstantina Kourou,Konstantinos P Exarchos,Costas Papaloukas,Prodromos Sakaloglou,Themis Exarchos,Dimitrios I Fotiadis

DOI: https://doi.org/10.1016/j.csbj.2021.10.006

2021-10-06

Abstract:Artificial Intelligence (AI) has recently altered the landscape of cancer research and medical oncology using traditional Machine Learning (ML) algorithms and cutting-edge Deep Learning (DL) architectures. In this review article we focus on the ML aspect of AI applications in cancer research and present the most indicative studies with respect to the ML algorithms and data used. The PubMed and dblp databases were considered to obtain the most relevant research works of the last five years. Based on a comparison of the proposed studies and their research clinical outcomes concerning the medical ML application in cancer research, three main clinical scenarios were identified. We give an overview of the well-known DL and Reinforcement Learning (RL) methodologies, as well as their application in clinical practice, and we briefly discuss Systems Biology in cancer research. We also provide a thorough examination of the clinical scenarios with respect to disease diagnosis, patient classification and cancer prognosis and survival. The most relevant studies identified in the preceding year are presented along with their primary findings. Furthermore, we examine the effective implementation and the main points that need to be addressed in the direction of robustness, explainability and transparency of predictive models. Finally, we summarize the most recent advances in the field of AI/ML applications in cancer research and medical oncology, as well as some of the challenges and open issues that need to be addressed before data-driven models can be implemented in healthcare systems to assist physicians in their daily practice.
Machine Learning Meets Cancer

Elena V. Varlamova,Maria A. Butakova,Vlada V. Semyonova,Sergey A. Soldatov,Artem V. Poltavskiy,Oleg I. Kit,Alexander V. Soldatov

DOI: https://doi.org/10.3390/cancers16061100

2024-03-09

Cancers

Abstract:The role of machine learning (a part of artificial intelligence—AI) in the diagnosis and treatment of various types of oncology is steadily increasing. It is expected that the use of AI in oncology will speed up both diagnostic and treatment planning processes. This review describes recent applications of machine learning in oncology, including medical image analysis, treatment planning, patient survival prognosis, and the synthesis of drugs at the point of care. The fast and reliable analysis of medical images is of great importance in the case of fast-flowing forms of cancer. The introduction of ML for the analysis of constantly growing volumes of big data makes it possible to improve the quality of prescribed treatment and patient care. Thus, ML is expected to become an essential technology for medical specialists. The ML model has already improved prognostic prediction for patients compared to traditional staging algorithms. The direct synthesis of the necessary medical substances (small molecule mixtures) at the point of care could also seriously benefit from the application of ML. We further review the main trends in the use of artificial intelligence-based technologies in modern oncology. This review demonstrates the future prospects of using ML tools to make progress in cancer research, as well as in other areas of medicine. Despite growing interest in the use of modern computer technologies in medical practice, a number of unresolved ethical and legal problems remain. In this review, we also discuss the most relevant issues among them.

oncology
Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases

Anita Bakrania,Narottam Joshi,Xun Zhao,Gang Zheng,Mamatha Bhat

DOI: https://doi.org/10.1016/j.phrs.2023.106706

Abstract:Liver cancers are the fourth leading cause of cancer-related mortality worldwide. In the past decade, breakthroughs in the field of artificial intelligence (AI) have inspired development of algorithms in the cancer setting. A growing body of recent studies have evaluated machine learning (ML) and deep learning (DL) algorithms for pre-screening, diagnosis and management of liver cancer patients through diagnostic image analysis, biomarker discovery and predicting personalized clinical outcomes. Despite the promise of these early AI tools, there is a significant need to explain the 'black box' of AI and work towards deployment to enable ultimate clinical translatability. Certain emerging fields such as RNA nanomedicine for targeted liver cancer therapy may also benefit from application of AI, specifically in nano-formulation research and development given that they are still largely reliant on lengthy trial-and-error experiments. In this paper, we put forward the current landscape of AI in liver cancers along with the challenges of AI in liver cancer diagnosis and management. Finally, we have discussed the future perspectives of AI application in liver cancer and how a multidisciplinary approach using AI in nanomedicine could accelerate the transition of personalized liver cancer medicine from bench side to the clinic.
Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration

Lise Wei,Dipesh Niraula,Evan D. H. Gates,Jie Fu,Yi Luo,Matthew J. Nyflot,Stephen R. Bowen,Issam M El Naqa,Sunan Cui

DOI: https://doi.org/10.1259/bjr.20230211

2023-09-06

British Journal of Radiology

Abstract:Multiomics data including imaging radiomics and various types of molecular biomarkers have been increasingly investigated for better diagnosis and therapy in the era of precision oncology. Artificial intelligence (AI) including machine learning (ML) and deep learning (DL) techniques combined with the exponential growth of multiomics data may have great potential to revolutionize cancer subtyping, risk stratification, prognostication, prediction and clinical decision-making. In this article, we first present different categories of multiomics data and their roles in diagnosis and therapy. Second, AI-based data fusion methods and modeling methods as well as different validation schemes are illustrated. Third, the applications and examples of multiomics research in oncology are demonstrated. Finally, the challenges regarding the heterogeneity data set, availability of omics data, and validation of the research are discussed. The transition of multiomics research to real clinics still requires consistent efforts in standardizing omics data collection and analysis, building computational infrastructure for data sharing and storing, developing advanced methods to improve data fusion and interpretability, and ultimately, conducting large-scale prospective clinical trials to fill the gap between study findings and clinical benefits.

radiology, nuclear medicine & medical imaging
Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development

Madhukiran Parvathaneni,Abduselam K. Awol,Monika Kumari,Ke Lan,Manisha Lingam

DOI: https://doi.org/10.22270/jddt.v13i1.5867

2023-01-15

Journal of Drug Delivery and Therapeutics

Abstract:Drug discovery has traditionally been a time consuming and expensive endeavor. Additionally, drugs weren’t as effectively designed as those that are being predicted and developed through AI and ML today. Machine learning is a form of artificial intelligence that develops and evolves based on experience (similarly to the human mind), and is more recently being utilized in drug discovery and design. The integration of AI and ML into the drug discovery and development process has allowed for higher target precision, lower toxicity, and better dosage formulations. AI more generally has been introduced to and has been leveraged at, each step of drug development, including target identification and validation, hit identification, as well as hit to lead optimization, and has been key in shortening the previously lengthy drug screening process. AI and ML has also been applied downstream in drug formulation where it has maximized resource utilization and is allowing for web-based 3D printing of drugs. Application of AI in the drug development process has also been extended to the modeling of novel drug-like compounds to predict their ADMET properties. This review will address the stages of drug discovery and development in which the application of AI and ML modeling has altered the traditional development of drugs. Keywords: Drug discovery, machine learning, artificial intelligence, computational drug development.
Artificial intelligence in cancer target identification and drug discovery

Yujie You,Xin Lai,Yi Pan,Huiru Zheng,Julio Vera,Suran Liu,Senyi Deng,Le Zhang

DOI: https://doi.org/10.1038/s41392-022-00994-0

IF: 39.3

2022-05-11

Signal Transduction and Targeted Therapy

Abstract:Abstract Artificial intelligence is an advanced method to identify novel anticancer targets and discover novel drugs from biology networks because the networks can effectively preserve and quantify the interaction between components of cell systems underlying human diseases such as cancer. Here, we review and discuss how to employ artificial intelligence approaches to identify novel anticancer targets and discover drugs. First, we describe the scope of artificial intelligence biology analysis for novel anticancer target investigations. Second, we review and discuss the basic principles and theory of commonly used network-based and machine learning-based artificial intelligence algorithms. Finally, we showcase the applications of artificial intelligence approaches in cancer target identification and drug discovery. Taken together, the artificial intelligence models have provided us with a quantitative framework to study the relationship between network characteristics and cancer, thereby leading to the identification of potential anticancer targets and the discovery of novel drug candidates.

biochemistry & molecular biology,cell biology
Artificial Intelligence Application for Anti-tumor Drug Synergy Prediction

Zheng Peng,Yanling Ding,Pengfei Zhang,Xiaolan Lv,Zepeng Li,Xiaoling Zhou,Shigao Huang

DOI: https://doi.org/10.2174/0109298673290777240301071513

IF: 4.74

2024-03-12

Current Medicinal Chemistry

Abstract:Abstract: Currently, the main therapeutic methods for cancer include surgery, radiation therapy, and chemotherapy. However, chemotherapy still plays an important role in tumor therapy. Due to the variety of pathogenic factors, the development process of tumors is complex and regulated by many factors, and the treatment of a single drug is easy to cause the human body to produce a drug-resistant phenotype to specific drugs and eventually leads to treatment failure. In the process of clinical tumor treatment, the combination of multiple drugs can produce stronger anti-tumor effects by regulating multiple mechanisms and can reduce the problem of tumor drug resistance while reducing the toxic side effects of drugs. Therefore, it is still a great challenge to construct an efficient and accurate screening method that can systematically consider the synergistic anti- tumor effects of multiple drugs. However, anti-tumor drug synergy prediction is of importance in improving cancer treatment outcomes. However, identifying effective drug combinations remains a complex and challenging task. This review provides a comprehensive overview of cancer drug synergy therapy and the application of artificial intelligence (AI) techniques in cancer drug synergy prediction. In addition, we discuss the challenges and perspectives associated with deep learning approaches. In conclusion, the review of the AI techniques' application in cancer drug synergy prediction can further advance our understanding of cancer drug synergy and provide more effective treatment plans and reasonable drug use strategies for clinical guidance.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
A comprehensive review on recent approaches for cancer drug discovery associated with artificial intelligence

Sanjeevi Pandiyan,Li Wang

DOI: https://doi.org/10.1016/j.compbiomed.2022.106140

IF: 7.7

2022-09-29

Computers in Biology and Medicine

Abstract:Through the revolutionization of artificial intelligence (AI) technologies in clinical research, significant improvement is observed in diagnosis of cancer. Utilization of these AI technologies, such as machine and deep learning, is imperative for the discovery of novel anticancer drugs and improves existing/ongoing cancer therapeutics. However, building a model for complicated cancers and their types remains a challenge due to lack of effective therapeutics that hinder the establishment of effective computational tools. In this review, we exploit recent approaches and state-of-the-art in implementing AI methods for anticancer drug discovery, and discussed how advances in these applications need to be considered in the current cancer therapeutics. Considering the immense potential of AI, we explore molecular docking and their interactions to recognize metabolic activities that support drug design. Finally, we highlight corresponding strategies in applying machine and deep learning methods to various types of cancer with their pros and cons.

engineering, biomedical,computer science, interdisciplinary applications,mathematical & computational biology,biology
Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies

Pratima Bichandarkoil Jayaram,Nalini Namasivayam

DOI: https://doi.org/10.4018/978-1-7998-8786-7.ch007

2022-01-01

Abstract:Improved cancer treatments are widely cited as a significant unmet medical need. Recent technological developments and the increasing availability of biological “big data” provide an unprecedented opportunity to systematically classify the primary genes and pathways involved in tumorigenesis. Artificial intelligence (AI) has shown great promise in many healthcare fields, including science and chemical discovery. The AI will explore and learn more using vast volumes of aggregated data, converting this data into “usable” information. The aim is to use current computational biology and machine learning systems to predict molecular behaviour and the probability of receiving a helpful medication, thus saving time and money on unnecessary tests. Clinical trials, electronic medical records, high-resolution medical images, and genomic profiles can all be used to help with drug growth. The discoveries made with these emerging technologies have the potential to lead to innovative therapeutic approaches.
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment

Chaoyi Zhang,Jin Xu,Rong Tang,Jianhui Yang,Wei Wang,Xianjun Yu,Si Shi

DOI: https://doi.org/10.1186/s13045-023-01514-5

IF: 28.5

2023-11-29

Journal of Hematology & Oncology

Abstract:Research into the potential benefits of artificial intelligence for comprehending the intricate biology of cancer has grown as a result of the widespread use of deep learning and machine learning in the healthcare sector and the availability of highly specialized cancer datasets. Here, we review new artificial intelligence approaches and how they are being used in oncology. We describe how artificial intelligence might be used in the detection, prognosis, and administration of cancer treatments and introduce the use of the latest large language models such as ChatGPT in oncology clinics. We highlight artificial intelligence applications for omics data types, and we offer perspectives on how the various data types might be combined to create decision-support tools. We also evaluate the present constraints and challenges to applying artificial intelligence in precision oncology. Finally, we discuss how current challenges may be surmounted to make artificial intelligence useful in clinical settings in the future.

oncology,hematology
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions

William Lotter,Michael J. Hassett,Nikolaus Schultz,Kenneth L. Kehl,Eliezer M. Van Allen,Ethan Cerami

DOI: https://doi.org/10.1158/2159-8290.cd-23-1199

IF: 28.2

2024-04-11

Cancer Discovery

Abstract:Artificial intelligence (AI) in oncology is advancing beyond algorithm development to integration into clinical practice. This review describes the current state of the field, with a specific focus on clinical integration. AI applications are structured according to cancer type and clinical domain, focusing on the four most common cancers and tasks of detection, diagnosis, and treatment. These applications encompass various data modalities, including imaging, genomics, and medical records. We conclude with a summary of existing challenges, evolving solutions, and potential future directions for the field. Significance: AI is increasingly being applied to all aspects of oncology, where several applications are maturing beyond research and development to direct clinical integration. This review summarizes the current state of the field through the lens of clinical translation along the clinical care continuum. Emerging areas are also highlighted, along with common challenges, evolving solutions, and potential future directions for the field.

oncology
Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy

Yu Cai,Rui Chen,Shenghan Gao,Wenqing Li,Yuru Liu,Guodong Su,Mingming Song,Mengju Jiang,Chao Jiang,Xi Zhang

DOI: https://doi.org/10.3389/fonc.2022.1054231

IF: 4.7

2023-01-09

Frontiers in Oncology

Abstract:The field of cancer neoantigen investigation has developed swiftly in the past decade. Predicting novel and true neoantigens derived from large multi-omics data became difficult but critical challenges. The rise of Artificial Intelligence (AI) or Machine Learning (ML) in biomedicine application has brought benefits to strengthen the current computational pipeline for neoantigen prediction. ML algorithms offer powerful tools to recognize the multidimensional nature of the omics data and therefore extract the key neoantigen features enabling a successful discovery of new neoantigens. The present review aims to outline the significant technology progress of machine learning approaches, especially the newly deep learning tools and pipelines, that were recently applied in neoantigen prediction. In this review article, we summarize the current state-of-the-art tools developed to predict neoantigens. The standard workflow includes calling genetic variants in paired tumor and blood samples, and rating the binding affinity between mutated peptide, MHC (I and II) and T cell receptor (TCR), followed by characterizing the immunogenicity of tumor epitopes. More specifically, we highlight the outstanding feature extraction tools and multi-layer neural network architectures in typical ML models. It is noted that more integrated neoantigen-predicting pipelines are constructed with hybrid or combined ML algorithms instead of conventional machine learning models. In addition, the trends and challenges in further optimizing and integrating the existing pipelines are discussed.

oncology
Artificial intelligence, machine learning, and drug repurposing in cancer

Ziaurrehman Tanoli,Markus Vähä-Koskela,Tero Aittokallio

DOI: https://doi.org/10.1080/17460441.2021.1883585

Abstract:Introduction: Drug repurposing provides a cost-effective strategy to re-use approved drugs for new medical indications. Several machine learning (ML) and artificial intelligence (AI) approaches have been developed for systematic identification of drug repurposing leads based on big data resources, hence further accelerating and de-risking the drug development process by computational means.Areas covered: The authors focus on supervised ML and AI methods that make use of publicly available databases and information resources. While most of the example applications are in the field of anticancer drug therapies, the methods and resources reviewed are widely applicable also to other indications including COVID-19 treatment. A particular emphasis is placed on the use of comprehensive target activity profiles that enable a systematic repurposing process by extending the target profile of drugs to include potent off-targets with therapeutic potential for a new indication.Expert opinion: The scarcity of clinical patient data and the current focus on genetic aberrations as primary drug targets may limit the performance of anticancer drug repurposing approaches that rely solely on genomics-based information. Functional testing of cancer patient cells exposed to a large number of targeted therapies and their combinations provides an additional source of repurposing information for tissue-aware AI approaches.
Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy

Alla Bulashevska,Zsófia Nacsa,Franziska Lang,Markus Braun,Martin Machyna,Mustafa Diken,Liam Childs,Renate König

DOI: https://doi.org/10.3389/fimmu.2024.1394003

IF: 7.3

2024-05-29

Frontiers in Immunology

Abstract:Cancer immunotherapy has witnessed rapid advancement in recent years, with a particular focus on neoantigens as promising targets for personalized treatments. The convergence of immunogenomics, bioinformatics, and artificial intelligence (AI) has propelled the development of innovative neoantigen discovery tools and pipelines. These tools have revolutionized our ability to identify tumor-specific antigens, providing the foundation for precision cancer immunotherapy. AI-driven algorithms can process extensive amounts of data, identify patterns, and make predictions that were once challenging to achieve. However, the integration of AI comes with its own set of challenges, leaving space for further research. With particular focus on the computational approaches, in this article we have explored the current landscape of neoantigen prediction, the fundamental concepts behind, the challenges and their potential solutions providing a comprehensive overview of this rapidly evolving field.

immunology
Multi-omics based artificial intelligence for cancer research

Lusheng Li,Mengtao Sun,Jieqiong Wang,Shibiao Wan

DOI: https://doi.org/10.1016/bs.acr.2024.06.005

Abstract:With significant advancements of next generation sequencing technologies, large amounts of multi-omics data, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have been accumulated, offering an unprecedented opportunity to explore the heterogeneity and complexity of cancer across various molecular levels and scales. One of the promising aspects of multi-omics lies in its capacity to offer a holistic view of the biological networks and pathways underpinning cancer, facilitating a deeper understanding of its development, progression, and response to treatment. However, the exponential growth of data generated by multi-omics studies present significant analytical challenges. Processing, analyzing, integrating, and interpreting these multi-omics datasets to extract meaningful insights is an ambitious task that stands at the forefront of current cancer research. The application of artificial intelligence (AI) has emerged as a powerful solution to these challenges, demonstrating exceptional capabilities in deciphering complex patterns and extracting valuable information from large-scale, intricate omics datasets. This review delves into the synergy of AI and multi-omics, highlighting its revolutionary impact on oncology. We dissect how this confluence is reshaping the landscape of cancer research and clinical practice, particularly in the realms of early detection, diagnosis, prognosis, treatment and pathology. Additionally, we elaborate the latest AI methods for multi-omics integration to provide a comprehensive insight of the complex biological mechanisms and inherent heterogeneity of cancer. Finally, we discuss the current challenges of data harmonization, algorithm interpretability, and ethical considerations. Addressing these challenges necessitates a multidisciplinary collaboration, paving the promising way for more precise, personalized, and effective treatments for cancer patients.
Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction

Tong Li,Yupeng Li,Xiaoyi Zhu,Xiaoyi Zhu,Yao He,Yanling Wu,Yanling Wu,Tianlei Ying,Tianlei Ying,Zhi Xie,Zhi Xie

DOI: https://doi.org/10.1016/j.semcancer.2023.02.007

IF: 17.012

2023-06-01

Seminars in Cancer Biology

Abstract:Cancer immunotherapy is a method of controlling and eliminating tumors by reactivating the body's cancer-immunity cycle and restoring its antitumor immune response. The increased availability of data, combined with advancements in high-performance computing and innovative artificial intelligence (AI) technology, has resulted in a rise in the use of AI in oncology research. State-of-the-art AI models for functional classification and prediction in immunotherapy research are increasingly used to support laboratory-based experiments. This review offers a glimpse of the current AI applications in immunotherapy, including neoantigen recognition, antibody design, and prediction of immunotherapy response. Advancing in this direction will result in more robust predictive models for developing better targets, drugs, and treatments, and these advancements will eventually make their way into the clinical setting, pushing AI forward in the field of precision oncology.

oncology

Fusing Artificial Intelligence and Machine Learning for Anti-Cancer Drug Discovery

Artificial intelligence for small molecule anticancer drug discovery

Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery

Artificial Intelligence and Anticancer Drug Development—Keep a Cool Head

Artificial Intelligence-Driven Computational Approaches in the Development of Anticancer Drugs

Applied machine learning in cancer research: A systematic review for patient diagnosis, classification and prognosis

Machine Learning Meets Cancer

Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases

Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration

Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development

Artificial intelligence in cancer target identification and drug discovery

Artificial Intelligence Application for Anti-tumor Drug Synergy Prediction

A comprehensive review on recent approaches for cancer drug discovery associated with artificial intelligence

Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies

Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment

Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions

Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy

Artificial intelligence, machine learning, and drug repurposing in cancer

Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy

Multi-omics based artificial intelligence for cancer research

Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction